Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Strategically Disrupting Drug Delivery
- Expanding the applicability of edible delivery technology within the drug industry
- Creating strategic partnerships through licensing agreements
- Breakthrough in nicotine absorption study supports further investigation into the many possible uses beyond the cannabis and nicotine industries
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a drug delivery platform innovator, partners with leading companies within the drug industry. The company is known primarily for removing objectionable flavors while improving the effectiveness of gastro-intestinal delivery of edible cannabinoid consumer products, but the company is now working to expand the applicability of its technology beyond the cannabis industry. DehydraTECH™ is Lexaria’s edible delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules.
This revolutionary technology makes it possible to deliver bioactive substances via oral ingestion, eliminating the need for unhealthy practices of inhalation or the addition of unhealthy sugars or sweeteners that are commonly used to mask taste. The implications are widespread and promise improvements in the delivery of NSAIDs and vitamins, as well as nicotine and more. The company is strategically positioned with patents issued in the U.S. and Australia (and more pending in over 40 countries) to enhance products and companies already established within their industry.
LXRP is disrupting the delivery of drugs or other active ingredients by strategically partnering, not competing, with industry leaders. The company recently announced a major new licensing agreement with Nuka Enterprises LLC. This 10-year agreement gives Nuka and its “1906” brand of cannabis chocolates a competitive technology advantage and increases the use of DehydraTECH™ from chocolate to candies, beverages, capsules, pills and topical creams. The company also entered into a five-year semi-exclusive rights agreement to use DehydraTECH™ for cannabis beverage applications in California with GP Holdings LLC.
LXRP’s research and interest go beyond the cannabis industry. Lexaria’s patented DehydraTECH™ is currently being analyzed in the lab for nicotine delivery. The findings suggest a prolongation of nicotine’s effectiveness with the Lexaria formulation, which may also be beneficial in controlling cravings over an extended period of time with smaller and fewer edible nicotine doses. This is good news for LXRP and its proprietary technology. The findings suggest that further investigation needs to be done into whether the technology could be used to help reduce unwanted side effects common to other drugs.
The possibility of partnerships reaches far beyond these two industries. Research efforts have shown the edible technology to be compatible with a wide range of consumer-related compounds. Higher bioavailability of drugs is often associated with lower overall doses of certain molecules, which pass on cost reduction to consumers as well as bypassing unwanted side effects of the drugs. This revolutionary technology is disrupting the delivery of drugs, allowing the consumer to ingest less of the harmful byproducts while enhancing the benefits.
For more information, visit the company’s website at www.LexarioBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Expanding the applicability of edible delivery technology within the drug industry
- Creating strategic partnerships through licensing agreements
- Breakthrough in nicotine absorption study supports further investigation into the many possible uses beyond the cannabis and nicotine industries
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a drug delivery platform innovator, partners with leading companies within the drug industry. The company is known primarily for removing objectionable flavors while improving the effectiveness of gastro-intestinal delivery of edible cannabinoid consumer products, but the company is now working to expand the applicability of its technology beyond the cannabis industry. DehydraTECH™ is Lexaria’s edible delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules.
This revolutionary technology makes it possible to deliver bioactive substances via oral ingestion, eliminating the need for unhealthy practices of inhalation or the addition of unhealthy sugars or sweeteners that are commonly used to mask taste. The implications are widespread and promise improvements in the delivery of NSAIDs and vitamins, as well as nicotine and more. The company is strategically positioned with patents issued in the U.S. and Australia (and more pending in over 40 countries) to enhance products and companies already established within their industry.
LXRP is disrupting the delivery of drugs or other active ingredients by strategically partnering, not competing, with industry leaders. The company recently announced a major new licensing agreement with Nuka Enterprises LLC. This 10-year agreement gives Nuka and its “1906” brand of cannabis chocolates a competitive technology advantage and increases the use of DehydraTECH™ from chocolate to candies, beverages, capsules, pills and topical creams. The company also entered into a five-year semi-exclusive rights agreement to use DehydraTECH™ for cannabis beverage applications in California with GP Holdings LLC.
LXRP’s research and interest go beyond the cannabis industry. Lexaria’s patented DehydraTECH™ is currently being analyzed in the lab for nicotine delivery. The findings suggest a prolongation of nicotine’s effectiveness with the Lexaria formulation, which may also be beneficial in controlling cravings over an extended period of time with smaller and fewer edible nicotine doses. This is good news for LXRP and its proprietary technology. The findings suggest that further investigation needs to be done into whether the technology could be used to help reduce unwanted side effects common to other drugs.
The possibility of partnerships reaches far beyond these two industries. Research efforts have shown the edible technology to be compatible with a wide range of consumer-related compounds. Higher bioavailability of drugs is often associated with lower overall doses of certain molecules, which pass on cost reduction to consumers as well as bypassing unwanted side effects of the drugs. This revolutionary technology is disrupting the delivery of drugs, allowing the consumer to ingest less of the harmful byproducts while enhancing the benefits.
For more information, visit the company’s website at www.LexarioBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
